Publications

Inhibition of the 3CL Protease and SARS-CoV‑2 Replication by Dalcetrapib

E. Niesor, G. Boivin, E. Rhéaume, et al.
ACS Omega
June 2021

VIEW PUBLICATION ›

Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib

D. Rhainds, C. Packard, M. Brodeur, et al.
AHA Journals
April 2021

VIEW PUBLICATION ›

The GenE Trial: A case study of precision medicine in the cardiovascular setting

Donald M Black MD, Therese Heinonen DVM, Marc Pfeffer MD and Jean-Claude Tardif MD
The Journal of Precision Medicine
August 2020

VIEW PUBLICATION ›

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

Schwartz G., Leiter L., Ballantyne C., et al.
American Diabetes Association: Diabetes Care
May 2020

VIEW PUBLICATION ›

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib

Black, D.M., Bentley, D., Chapel, S., et al.
Clinical Pharmacokinetics
November 2018

VIEW PUBLICATION ›

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes

Tardif J.C., Rhainds D., Brodeur M., et al.
Circulation: Cardiovascular Genetics
August 2016

VIEW PUBLICATION ›

Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib.Circulation Cardiovascular Genetics

Tardif  J.C., Rheaume E., Lemieux Perreault L-P., et. al.
Circulation: Cardiovascular Genetics
January 2015

VIEW PUBLICATION ›